Vaccines for Monkeypox Prevention: Jynneos and ACAM2000
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
The Novavax COVID-19 Vaccine, Adjuvanted is administered intramuscularly as a 2-dose primary series (0.5mL each), separated by 3 weeks.
The approval was based on data from a phase 3 trial which included 2260 participants 12 to 15 years of age enrolled in the United States.
In total, 1.6 million doses of the Jynneos vaccine will be available this year.
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
NVX-CoV2373 is engineered from the genetic sequence of SARS-CoV-2 using the Company’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein.
Priorix is administered as a 2-dose series (each dose is approximately 0.5mL) via subcutaneous injection.
Dr Robert Popovian discusses access to immunization services among adults in low-income communities and efforts to expand pharmacists’ authority to administer vaccines to increase vaccination rates for this vulnerable population.
In this interview, Paritosh Prasad, MD, provides insight into the recent outbreak of monkeypox.